Novartis first company accredited with global CEO Cancer Gold Standard
- Details
- Category: Novartis
Novartis is the first company to earn global CEO Cancer Gold Standard accreditation by the non-profit organization CEO Roundtable on Cancer, a group of cancer fighting CEOs from a variety of industries, including healthcare. The designation recognizes the company's efforts to provide support to Novartis associates in the prevention, diagnosis and treatment of cancer.
GSK launches $50 million venture capital fund to invest in pioneering bioelectronic medicines and technologies
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline has announced the launch of Action Potential Venture Capital (APVC) Limited, a new $50 million strategic venture capital fund that will invest in companies that pioneer bioelectronic medicines and technologies. The fund's first investment will be in SetPoint Medical, a California company considered a trailblazer in creating implantable devices to treat inflammatory diseases.
Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival
- Details
- Category: Novartis
Novartis has announced that results of a global Phase III study showed that Afinitor® (everolimus) did not extend overall survival compared to placebo in patients with locally advanced or metastatic hepatocellular carcinoma (HCC) after progression on or intolerance to sorafenib[1].
AstraZeneca PLC second quarter and half year results 2013
- Details
- Category: AstraZeneca
AstraZeneca has announced that the revenue in the second quarter declined by 4 percent at constant exchange rates (CER), as the impact from products with recent loss of exclusivity has moderated from the levels experienced in recent quarters. Revenue for the rest of the portfolio was up 4 percent, fuelled by a double-digit increase from the five growth platforms.
GSK adds to its commitment to GAVI Alliance to help protect millions more children against infectious diseases
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) has increased its commitment to the GAVI Alliance to provide vaccines to developing countries, helping to protect millions more children against infectious diseases. Under this new agreement, GSK will provide an additional 240 million doses of Synflorix™ to developing countries over the next ten years, helping protect up to 80 million more children from pneumococcal diseases such as meningitis and pneumonia.
Pfizer to create separate, internal, global Innovative and Value businesses
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) has announced plans to move forward to internally separate its commercial operations into three business segments, two of which will include Innovative business lines and a third which will include the Value business line. Each of the three segments will include developed markets and emerging markets.
Bristol-Myers Squibb and Samsung BioLogics announce biopharmaceutical manufacturing relationship
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Samsung BioLogics today announced the companies have entered into a 10-year agreement under which Samsung BioLogics will manufacture a commercial antibody cancer drug for Bristol-Myers Squibb at its recently completed plant in Songdo Incheon, South Korea.
More Pharma News ...
- Pfizer statement on PhRMA-EFPIA principles for responsible clinical trial data sharing
- Bristol-Myers Squibb reports second quarter 2013 financial results
- AstraZeneca and Bristol-Myers Squibb resubmit dapagliflozin New Drug Application
- Novartis delivered growth across all divisions in second quarter
- Benefits of Pradaxa® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure
- GSK announces US submission for dabrafenib/trametinib combination in metastatic melanoma
- Roche halts investigation of aleglitazar